PT  - JOURNAL ARTICLE
AU  - Paproski, Robert J.
AU  - Wuest, Melinda
AU  - Jans, Hans-Sonke
AU  - Graham, Kathryn
AU  - Gati, Wendy P.
AU  - McQuarrie, Steve
AU  - McEwan, Alexander
AU  - Mercer, John
AU  - Young, James D.
AU  - Cass, Carol E.
TI  - Biodistribution and Uptake of 3′-Deoxy-3′-Fluorothymidine in ENT1-Knockout Mice and in an ENT1-Knockdown Tumor Model
AID  - 10.2967/jnumed.110.076356
DP  - 2010 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 1447--1455
VI  - 51
IP  - 9
4099  - http://jnm.snmjournals.org/content/51/9/1447.short
4100  - http://jnm.snmjournals.org/content/51/9/1447.full
SO  - J Nucl Med2010 Sep 01; 51
AB  - 18F-3′-Deoxy-3′-fluorothymidine (18F-FLT) is a PET tracer that accumulates in proliferating tissues. The current study was undertaken to determine whether equilibrative nucleoside transporter 1 (ENT1) is important for 18F-FLT uptake in normal tissues and tumors. Methods: ENT1-knockout (ENT1−/−) mice were generated and compared with wild-type (ENT1+/+) mice using small-animal 18F-FLT PET. In addition, ENT1+/+ mice were also injected with the ENT1 inhibitor nitrobenzylmercaptopurine ribonucleoside phosphate (NBMPR-P) at 1 h before radiotracer injection, followed by 18F-FLT small-animal PET. Tissues of interest were analyzed for thymidine kinase 1 and nucleoside transporters by immunoblotting and immunohistochemistry, respectively, and plasma thymidine levels were analyzed by liquid chromatography–mass spectrometry. Human lung carcinoma A549 cells were stably transfected with pSUPER-producing short-hairpin RNA against human ENT1 (hENT1) or a scrambled sequence with no homology to mammalian genes (A549-pSUPER-hENT1 and A549-pSUPER-SC, respectively). Cultured transfected cells were characterized for hENT1 transcript levels and 18F-FLT uptake using real-time polymerase chain reaction and 3H-FLT uptake assays, respectively. Transfected A549 cells were grown as xenograft tumors in NIH-III mice, which were analyzed by 18F-FLT small-animal PET. Results: Compared with noninjected ENT1+/+ mice, ENT1+/+ mice injected with NBMPR-P and ENT1−/− mice displayed a reduced percentage injected dose per gram (%ID/g) for 18F-FLT in the blood (84 and 81%, respectively) and an increased %ID/g for 18F-FLT in the spleen (188 and 469%, respectively) and bone marrow (266 and 453%, respectively). ENT1−/− mice displayed 1.65-fold greater plasma thymidine levels than did ENT1+/+ mice. Spleen tissue from ENT1+/+ and ENT1−/− mice displayed similar thymidine kinase 1 protein levels and significant concentrative nucleoside transporter 1 and 3 staining. Compared with A549-pSUPER-SC cells, A549-pSUPER-hENT1 cells displayed 0.45-fold hENT1 transcript levels and 0.68-fold 3H-FLT uptake. Compared with A549-pSUPER-SC xenograft tumors, A549-pSUPER-hENT1 xenograft tumors displayed 0.76-fold %ID/g values (ex vivo γ-counts) and 0.65-fold maximum standardized uptake values (PET image analysis) for 18F-FLT uptake at 1 h after tracer injection. Conclusion: Loss of ENT1 activity significantly affected 18F-FLT biodistribution in mice and 18F-FLT uptake in xenograft tumors, suggesting that nucleoside transporters are important mediators of 18F-FLT uptake in normal and transformed cells.